Sanofi announced that it has filed a new drug application (NDA) with the FDA for the fixed-ratio combination of its diabetes drugs, Lantus (insulin glargine, 100 units/mL) and Lyxumia (lixisenatide). Sanofi is looking to get the fixed-ratio combination approved as a single daily injection for the treatment of adults with type 2 diabetes.